openPR Logo
Press release

US Antidiabetics Drug Market Outlook 2022 Report Download

01-11-2018 08:42 AM CET | Health & Medicine

Press release from: Kuick Resarch

US Antidiabetics Drug Market Outlook 2022 Report Download

“US Antidiabetics Drug Market Outlook 2022” report gives clinical and non-clinical insight on trends associated with the development of Antidiabetics drug market in US. Report helps to identify the diabetes epidemiology (Prevalence of Type 1 and 2 Diabetes) in the US market along with the associated economic burden and productivity loss.

“US Antidiabetics Drug Market Outlook 2022” report highlights:

* US Diabetes Epidemiology
* US Antidiabetics Market Overview
* Key Marketed Antidiabetic Drugs in US
* US Biosimilar Insulin Market
* US Antidiabetics Drug Market Future Prospects

Download Sample

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink: https://www.kuickresearch.com/report-us-antidiabetics-drug-market-outlook-2022.php

Table of Contents

Antidiabetics: Regimen for Diabetes Mellitus
1.1 Prologue Towards Diabetes
1.2 Preface to Antidiabetics

Antiquity of Managing Diabetes Mellitus
2.1 Trajectory from Diabetes to Insulin
2.2 Historical En Route towards Oral Diabetic Medication

Treatments Available for Diabetes Mellitus
3.1 Non-Pharmacological Approaches for Diabetes Mellitus
3.2 Pharmacological Approaches for Diabetes Mellitus

Cataloguing of Antidiabetic Agents
4.1 Antidiabetic: Oral Agents
4.1.1 Biguanides
4.1.2 Thiazolidinediones (TZDs)
4.1.3 Sulfonylureas
4.1.4 Meglitinides
4.1.5 andalpha;- Glucosidase Inhibitors
4.1.6 Dipeptidyl Peptidase-4 Inhibitor
4.1.7 Bile Acid Sequestrants (BAS)
4.1.8 Dopamine Agonist-2

Antidiabetic: Injectable Drugs
5.1 Insulin: A life saving Modality
5.2 Non-Insulin Alternatives for Diabetes Mellitus

US Diabetes Epidemiology
6.1 Prevalence of Type 1 and 2 Diabetes
6.2 Economic Burden Associated with Type 1 and 2 Diabetes: Productivity Loss and Medical Bills

US Antidiabetics Market Overview
7.1 Antidiabetic Injectable Market Trends in US
7.2 Antidiabetic Oral Drugs Market Trends in US
7.3 Commending Trends of Antidiabetics

US: Key Marketed Antidiabetic Drugs
8.1 Insulin Degludec (Tresiba)- Injection
8.2 Insulin Lispro - Injection
8.3 Insulin Inhalation(Afrezza) - Inhalation
8.4 Insulin Glargine (Toujeo) - Injection
8.5 Insulin Glulisine (Apidra) - Injection
8.6 Insulin Aspart (NovoLog) - Injection
8.7 Insulin Detemir (Levemir FlexTouch) - Injection
8.8 Insulin Glargine (Lantus) - Injection
8.9 Insulin Aspart/Insulin Protamine Aspart (NovoLog) - Injection

US Biosimilar Insulin Market: Glargine Basaglar andndash; The First “Biosimilar” Insulin
9.1 First Insulin Biosimilar
9.2 Impact of Basaglar Launch

US Antidiabetics Drug Market Dynamics
10.1 Accelerative Parameters
10.2 Major Challenges

US Antidiabetics Drug Market Future Prospects

Competitive Landscape
12.1 AstraZeneca
12.2 Bayer
12.3 Boehringer Ingelheim
12.4 Eli-Lilly
12.5 Johnson and Johnson
12.6 Merck
12.7 Novartis
12.8 Novo Nordisk
12.9 Sanofi
12.10 Takeda

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release US Antidiabetics Drug Market Outlook 2022 Report Download here

News-ID: 895181 • Views: 266

More Releases from Kuick Resarch

Global CFTR Modulators Market Opportunity Clinical Trials Insight 2026
“Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2026” Report Highlights: • Global CFTR Modulators Market Opportunity: > US$ 20 Billion • Global CFTR Modulators Market Growth: 42% CAGR (2017 -2020) • Global CFTR Modulators Market Growth In 2020: 55% • Global CFTR Modulators Pipeline: 30 Drug • Commercially Available Bispecific Antibodies: 4 Drugs • Trikafta Market Share 2020: > 50% Download Report: https://www.kuickresearch.com/report-global-cystic-fibrosis-cftr-modulators-therapeutics-market-size-vertex-trikafta-cftr-potentiators-clinical-trials-research “Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2026” provides
Gamma Delta T Cell Cancer Therapy Opportunity Clinical Trials Insight 2026
“Gamma Delta T Cell Cancer Therapy Opportunity & Clinical Trials Insight 2026” Report Highlights: • Commercialization Market Potential After Market Launch: > USD 4 Billion • Insight on Key Drugs In Research & Development • Global Gamma Delta T Cell Cancer Therapy Clinical Trials Insight • Gamma Delta T Cell Cancer Therapy In clinical Trials: > 15 Therapies • Gamma Delta T Cell Cancer Therapy Market Opportunity By Cancer Type • Adopted Approaches for Gamma Delta T Cell Therapy Download
Global Peptide Drug Conjugate Clinical Trial Report 2026
Global Peptide Drug Conjugate Market & Clinical Trials Insight 2026 Report Highlights: • First FDA Approved Peptide Drug Conjugate: Pepaxto (Melphalan Flufenamide) • Pepaxto Clinical & Commercial Insight: Dosage, Patent, Price, Sales Forecast • Peptide Drug Conjugate Sales Opportunity: US, Europe, Japan & South Korea • Global Peptide Drug Conjugate Clinical Pipeline: > 20 Drugs • Clinical Trials Insight by Company, Country, Indication • Patent Insight of Peptide Drug Conjugates • Profile & Clinical Pipeline Insight of Companies Developing Peptide Drug Conjugates Download Report: https://www.kuickresearch.com/report-global-peptide-drug-conjugate-antibodies-antibody-market-pepaxto-melphalan-flufenamide-melflufen-clinical-trials-fda-approved-oncology-cancer-peptide-clinical-pipeline “Global Peptide
Global Trispecific Antibodies Market Opportunity & Clinical Trials Insight 2024
"Global Trispecific Antibodies Market Opportunity & Clinical Trials Insight 2024" Report Highlights: • Commutative Market Opportunity During Initial 5 years of Commercialization: > US$ 2 Billion • Trispecific Antibodies In Clinical Trials: > 8 Antibodies • Highest Phase of Development: Phase I/II • Cancer Dominating Trispecific Antibodies Trials: > 5 Antibodies • Numab Therapeutics Dominating the Trispecific Development Pipeline • Prevention & Second Line Therapy Key Focus of Development of Trispecific Antibodies Download Report: https://www.kuickresearch.com/report-global-trispecific-antibodies-antibody-market-sales-size-companies-cancer-trispecific--clinical-trials-sar441236--development-conjugate-immunogenicity Trispecific cancer antibody therapy market at

All 5 Releases


More Releases for Antidiabetic

Global Antidiabetic Biguanides Sales Market Advanced Technologies and Developmen …
Qyresearchreports include new market research report "Global Antidiabetic Biguanides Sales Market Report 2017" to its huge collection of research reports. This report on the global Antidiabetic Biguanides market has been developed by a selected group of professional market research analysts, with a solitary goal to present the existing scenario of the market for Antidiabetic Biguanides and shed light on its growth prospects. The report targets audiences such as manufacturers of Antidiabetic
Oral Antidiabetic (OAD) Treatment Market Snapshot by 2017 – 2025
Diabetic is the condition where the sugar (glucose) level is high in the blood or the production of the insulin is inadequate. Diabetes main type the very first one is Type 1 and the second is Type 2, both the diabetic are most commonly find in the current scenario, apart from this many other diabetics case are also been listed as gestational diabetes and others. The world is moving toward
Antidiabetic Biosimilars Market Expected to Grow Globally
Antidiabetic biosimilars market overview Antidiabetics help control blood glucose levels in diabetic patients. Various types of antidiabetics include biguanides, thiazolidinediones, DPP-IV inhibitors, α-glucosidase Inhibitors, sulfonylureas, insulin, and GLP-1 receptor agonists such as exenatide. A biosimilar product is biological product that is approved on the basis that it is highly similar to a FDA approved biological product known as a reference product. Biosimilar manufacturers need to generate data from lab testing and
03-07-2017 | Health & Medicine
SA-BRC
Antidiabetic Drugs Market and Pipeline Assessment
Diabetes is a major lifestyle disorder affecting millions of individuals globally. The disorder is also linked with other complications such as diabetic retinopathy, diabetic foot ulcers, nephropathy and cardiovascular complications among others. Wide spread global prevalence and rising incidence rate has made the antidiabetic drugs market attractive for pharmaceutical drug manufacturers. Introduction of superior products in the recent past and increasing patient compliance are other factors driving the diabetes treatment
Global Antidiabetic Thiazolidinediones Market Research Report 2017
The research report on the global Antidiabetic Thiazolidinediones market studies the market in the past based on which estimates are presented for the future. The report looks into vital market indicators, trends, and opportunities that will have a bearing on the development of this market. The report begins with an outline of terms and terminologies, classifications, and applications that are standard conventions in the global Antidiabetic Thiazolidinediones market. A glance into
Antidiabetic Biosimilars Market, Company Analysis and Forecast to 2024
Antidiabetic biosimilars market overview Antidiabetics help control blood glucose levels in diabetic patients. Various types of antidiabetics include biguanides, thiazolidinediones, DPP-IV inhibitors, α-glucosidase Inhibitors, sulfonylureas, insulin, and GLP-1 receptor agonists such as exenatide. A biosimilar product is biological product that is approved on the basis that it is highly similar to a FDA approved biological product known as a reference product. Biosimilar manufacturers need to generate data from lab testing and